Menogenix Inc

Greffex is a genetic engineering company based in Aurora, CO, specializing in next-generation adenoviral vector technology and a superior vaccine platform. Their innovative approach involves fully deleting all endogenous adenoviral genes without the use of helper viruses, resulting in vaccines that better focus the immune system, minimize interference, and allow for multiple repeat uses of the same construct.

Originally focused on gene therapy, Greffex has now shifted its primary focus to vaccine commercialization, with three vaccine candidates in clinical trials, including a COVID-19 vaccine. Their vaccines offer advantages such as single-dose administration, easy distribution, and a cost-efficient production process. With an impressive track record in animal trials and a portfolio of patents, Greffex is poised to become a global solution for mitigating pandemics and developing effective vaccines.

Generated from the website